Ontology highlight
ABSTRACT: Background
Inflammatory bowel diseases (IBDs) pose significant challenges in terms of treatment non-response, necessitating the development of novel therapeutic approaches. Although biological medicines that target TNF-α (tumour necrosis factor-α) have shown clinical success in some IBD patients, a substantial proportion still fails to respond.Methods
We designed bispecific nanobodies (BsNbs) with the ability to simultaneously target human macrophage-expressed membrane TNF-α (hmTNF-α) and IL-23. Additionally, we fused the constant region of human IgG1 Fc (hIgG1 Fc) to BsNb to create BsNb-Fc. Our study encompassed in vitro and in vivo characterization of BsNb and BsNb-Fc.Results
BsNb-Fc exhibited an improved serum half-life, targeting capability and effector functio
SUBMITTER: Wang J
PROVIDER: S-EPMC10966562 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature